
TOI Stock Forecast & Price Target
TOI Analyst Ratings
Bulls say
The Oncology Institute Inc experienced a remarkable 41.6% year-over-year growth in total revenue for the fourth quarter, surpassing estimates by 1.5%, indicating strong demand and effective operational performance. The partnership with Helios is anticipated to enhance margins significantly by 2026 and 2027, with expectations for margins to expand back to the 12%-15% range as contracts mature. Furthermore, the company is poised for sustainable positive earnings growth, supported by the addition of $30 million to $35 million in capitated revenue from year-to-date deals, positioning the company favorably within the expanding oncology market.
Bears say
The Oncology Institute Inc. is facing significant financial challenges, as evidenced by a substantial year-over-year decline of 71.4% in revenue from its Clinical Trials & Other segment, which generated only $0.7 million. The company reported an adjusted EBITDA of $0.1 million, representing a marginal 0.1% margin, which fell well short of expectations due to lower gross margins and ongoing contract losses impacting profitability. Additionally, with dispensary margins affected by changes in fees leading to a $15 million headwind, the company’s growth trends in oncology appear to be flat or in low single digits, raising concerns about its ability to achieve projected break-even EBITDA by late 2025.
This aggregate rating is based on analysts' research of The Oncology Institute and is not a guaranteed prediction by Public.com or investment advice.
TOI Analyst Forecast & Price Prediction
Start investing in TOI
Order type
Buy in
Order amount
Est. shares
0 shares